Company news
Filament Health Corp news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Filament Health announces interim results from phase i clinical trial at the university of california san francisco
May 30, 2023
Filament Health announces first ever Nagoya Protocol-compliant shipment of iboga from Gabon
May 17, 2023
Filament Health announces first quarter 2023 financial results and operational highlights
May 12, 2023
Filament Health to host virtual investor update
May 8, 2023
Filament Health announces spring 2023 event and media appearances
April 25, 2023
Filament Health and PharmAla biotech announce release of GMP MDMA capsules
April 11, 2023
Filament Health reports Q4 and year end 2022 financial results and operational highlights
March 31, 2023
Filament Health announces FDA approval of phase ii clinical trial studying psilocybin for methamphetamine use disorder
March 15, 2023
Filament Health announces second psilocybin supply agreement with the centre for addiction and Mental Health
February 14, 2023
Filament Health announces clinical trial approval in partnership with Psychiatric Centre Copenhagen
January 18, 2023
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
January 10, 2023
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
January 10, 2023
Filament Health announces CEO year end letter and change to board of directors
December 30, 2022
Filament Health and psyence announce worldwide licensing agreement of psilocybin capsule for palliative care
December 15, 2022
Filament Health announces new united states patent issuances
November 30, 2022
Filament Health announces psilocybin supply agreement with the centre for addiction and mental health
November 17, 2022
Filament Health announces third quarter 2022 financial results and operational highlights
November 10, 2022
Filament Health to host virtual investor update
October 12, 2022
Filament Health and ATMA journey centers announce 14 subjects dosed in health canada-approved psilocybin clinical trial
September 1, 2022
Filament Health appoints new members to board of directors and advisory council
August 24, 2022
Filament Health announces eighth patent issuance
August 17, 2022
Filament Health announces second quarter 2022 financial results and Operational Highlights
August 15, 2022
Filament Health announces participation in Project Solace
July 28, 2022
Filament Health announces closing of $2,500,080 private placement
July 13, 2022
Filament Health issued third patent by United States Patent and trademark office
July 12, 2022
Filament Health announces first dosing in groundbreaking FDA-approved psilocin clinical trial
July 7, 2022
Filament Health announces sixth patent issuance
July 6, 2022
Filament Health announces private placement of units and convertible debenture units of up to $2,500,000
June 30, 2022
Filament Health announces annual general meeting voting results
June 28, 2022
Filament Health announces patient dosing through health canada special access program
June 16, 2022
Filament Health cultivates 70th psychedelic mushroom variety and announces annual general meeting
June 10, 2022
Filament Health and Jaguar Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications
June 9, 2022
Filament Health is issued second patent by United States Patent and Trademark Office and reports Q1 results
May 17, 2022
Filament Health announces fourth patent issuance
April 27, 2022
Filament Health and psyence enter into exclusive licensing agreement for natural psilocybin products
April 19, 2022
Filament Health is issued patent by united states patent and trademark office
April 13, 2022
Filament Health announces pre-ind meeting with united states food and drug administration
April 12, 2022
Filament Health to participate in prominent psychedelic investor conferences in April 2022
April 7, 2022
Filament Health reports Q4 and year end 2021 financial results and operational highlights
March 31, 2022
Filament Health announces second patent issuance
March 23, 2022
Filament Health to Participate in the 34th Annual Roth Conference
March 8, 2022
Filament Health and ATMA Journey Centers Announce Licensing Agreement
February 23, 2022
Filament Health refiles Q2 and Q3 interim financial statements and MD&A
February 22, 2022
Filament Health and Cybin Therapeutics announce approval for phase ii clinical trial for depression
January 31, 2022
Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers
January 26, 2022
Filament Health and Cybin Therapeutics announce licensing agreement
January 14, 2022
Filament Health recognizes the restoration of access to restricted drugs via the Health Canada special access program
January 5, 2022
Filament Health announces health canada approval for phase ii trial administering new psilocybin microdose formulation
January 4, 2022
Filament Health to Participate in Key Psychedelics Conferences in December 2021
December 1, 2021
Filament Health Reports Third Quarter 2021 Financial Results and Operational Highlights
November 15, 2021
Decks
- SPAC Merger (October 2023)
SPAC merger · 27 slides · Oct 2, 2023
- SPAC Merger (July 2023)
SPAC merger · 28 slides · Jul 24, 2023